Cardiovascular magnetic resonance from basics to clinical applications.
The increasingly sophisticated treatment of patients with cardiac disorders has created the need for accurate and reproducible measurements of cardiac chamber volumes and function. (2) CMR has the ability to provide this information as well as assess edema, perfusion, viability and vascular anatomy.
Techniques of CMR Ventricular morphology
Black blood imaging can be used to create still-frame images with high spatial resolution for morphologic analysis (Figure 1). Bright-blood steady state free precession (SSFP) sequences provide moving cine images with a high signal-to-noise ratio (SNR) and excellent endocardial definition. Standard views are derived from their echocardiography counterparts; 4-chamber, 2-chamber (vertical long axis), left ventricular outflow tract (3-chamber), and short axis stacks (Figure 2). Morphologic variants of atrial, ventricular, valvular, arterial and venous structures can be imaged with unsurpassed definition. (3) The ability to image in any plane within the thorax is a unique strength of CMR, of particular advantage in congenital disorders.
Left ventricular function
Cardiovascular MR measurements of left ventricular (LV) function (Figure 2), are usually obtained from a series of ECG-gated SSFP images obtained in the short axis view. (4) Using either the 2- or 4chamber view as a reference, a short-axis stack is prescribed from the plane of the mitral valve orthogonal to the long axis of the ventricle in end-diastole. A stack of images extending to the cardiac apex is then acquired during suspended respiration, at a slice thickness of approximately 6 to 8 mm, with 2 mm interslice gap. Using either automated or manual techniques, the endocardial and epicardial borders are traced for each slice and the ventricular volumes are calculated. Reproducibility is best obtained by including the papillary muscles and trabeculae in the LV volume (Figure 2). (5) CMR remains the gold standard for measurements of LV mass, volume and ejection fraction (LVEF), as well as for regional wall-motion abnormalities, (6,7) and is more reproducible than echocardiography. (8)
The major source of error occurs at the basal slice during ventricular systole, because of
* the fixed imaging plane, and
* the descent of the mitral valve towards the LV apex, moving through the imaging plane.
Allow for LV shortening by careful cross-referencing of planes to delineate the position of the mitral annulus at end-systole and end-diastole.
Right ventricular function
Accurate right ventricular (RV) assessment demands 3-dimensional techniques because of the non-geometric shape of the ventricle. The RV position has also traditionally made reliable echocardiographic measurements difficult. RV dysfunction, as assessed by CMR, predicts a poor prognosis late after myocardial infarction (MI), (9) and is of particular importance in pulmonary hypertension and adult congenital heart disease. (3)
[FIGURE 1 OMITTED]
[FIGURE 2 OMITTED]
In many centers, it is customary to use the LV short axis view to assess RV volume. However, the basal dimension of the RV is considerably larger than the base of the LV, and when errors occur in the base of the RV they may significantly affect accuracy, usually by underestimating RV volumes. (8,10) The tricuspid valve annular plane lies apical of the mitral valve plane. When the same series of LV short axis views is used for RV measurements as for LV measurements, the basal end-diastolic and end-systolic slice positions may be difficult to determine. This is compounded because, in most cases, both RV and atrial walls are thin, rendering it difficult to identify the exact plane of the tricuspid valve. RV quantification can be improved by using axial views or, preferably, dedicated RV sequences where the tricuspid valve is imaged in the margin of the slice. (10,11) Axial imaging has disadvantages in congenital heart diseases where the cardiac axis and the skeletal axis may not align, leading to inaccuracies in delineating the atrio-ventricular plane.
Late gadolinium enhancement
Tissue characterization with late gadolinium enhancement (LGE) is one of the unique properties of CMR. This phenomenon results from inherent relative differences in the volume of distribution of gadolinium (Gd) between normal and abnormal myocardium. (12,13) Gadolinium is normally confined to the extracellular and interstitial space (e.g., it does not penetrate intact myocardial cell membranes). Changes to the interstitium, such as infiltration or fibrosis, increase the volume of distribution, allowing a larger amount of Gd to penetrate into the tissue. T1-weighted (T1W) CMR imaging performed early after Gd administration is used for assessment of myocardial perfusion during "first pass" entry into the myocardial microcirculation, analogous to single-photon emission computed tomography (SPECT) perfusion imaging of the myocardium. Imaging performed late (10 to 20 min) after Gd administration allows washout from the myocardial circulation. Myocardial signal is nulled by the use of an inversion pulse, leaving normal myocardium appearing black and areas of abnormal myocardium appearing relatively bright due to residual Gd in the tissue (hence the term "late gadolinium enhancement"). (14-16) Myocyte necrosis results in loss of cell membrane integrity, allowing intracellular accumulation of Gd as occurs in LGE imaging of patients with MI. (14,16-18)
[FIGURE 3 OMITTED]
[FIGURE 4 OMITTED]
[FIGURE 5 OMITTED]
T2-weighted 'edema' imaging
T2-weighted (T2W) short-tau inversion recovery (STIR) imaging is a CMR sequence sensitive to increased myocardial water content, allowing the delineation of high-signal areas of myocardial edema. Increased mobile water content associated with edema appears hyperintense on T2W-STIR images (Figure 3). (19) Quantification of myocardial edema, using tissue signal thresholds, has been shown to strongly correlate with ischemic time. (20-22) Myocardial edema may be present after any form of myocardial injury such as myocardial ischemia, acute infarction, myocarditis, sarcoidosis or trauma. (19) CMR is able to assist in the diagnosis and surveillance of a range of cardiac disorders (Table 1).
[FIGURE 6 OMITTED]
Clinical role and indications for CMR Ischemic cardiomyopathy
Early studies show that increased signal in the myocardium following intravenous Gd accurately depicted irreversible ischemic myocardial injury independent of age. (23,24) This was subsequently confirmed by others. (25) The presence and transmural extent of LGE following myocardial ischemia (Figures 3B and 4) gives important predictive information about the likelihood of functional recovery after revascularization. (26-29) CMR is now considered the gold standard investigation for the assessment of myocardial viability.
The extent of LGE is also predictive of LV remodelling in patients with HF from both ischemic and non-ischemic causes. (30) Previous reports have shown that the presence of LGE can distinguish ischemic from non-ischemic dilated cardiomyopathy with good sensitivity and specificity (Figure 5). (31,32) However, patients with either severe left main or diffuse coronary disease may not have undergone infarction, and therefore may not exhibit ischemic-type LGE, despite large areas of ventricular hibernation. CMR with LGE combined with CT coronary angiography may improve the noninvasive detection of ischemia as a cause for heart failure with high sensitivity and specificity. (33) Stress CMR perfusion imaging may also have a role in this scenario. (34)
The presence of mid-wall fibrosis as demonstrated by LGE (Figure 5) has also been shown to correlate with a higher rate of all-cause mortality and hospitalization in patients with non-ischemic dilated cardiomyopathy (DCM). (35,36) In a group of patients with DCM, the presence of mid-wall LGE occurred with poorer ejection fractions and larger volumes when compared with a group of patients with DCM and absence of mid-wall enhancement (Figure 6). (37) The extent of this interstitial fibrosis has also been assessed by the use of T1 mapping following intravenous Gd. (38) Interstitial fibrosis is a final common pathway for many patients suffering myocardial damage from various etiologies. (39) Measurements of T2 signal intensity and relaxation times also correlate with biopsy-proven heart transplant rejection. (40) The degree of interstitial fibrosis on CMR also correlates with increased arrhythmic events in patients with hypertrophic cardiomyopathy. (41,42)
[FIGURE 7 OMITTED]
Infiltrative cardiomyopathies, which may present either with systolic or diastolic heart failure, arrhythmias or sudden cardiac death, can be difficult to diagnose with traditional imaging techniques. CMR provides accurate assessment of ventricular morphology and LGE, allowing imaging of abnormal areas of myocardium, with particular patterns of LGE correlating with the underlying infiltrative diagnosis. (43) Such conditions include sarcoidosis, hypertrophic cardiomyopathy, connective tissue diseases, endomyocardial fibrosis and amyloid infiltration (Figure 7). (44-47) These conditions have patterns of LGE that may be characteristic, and assist in diagnosis, when combined with the clinical features and ventricular morphology (Table 2). Knowledge of such etiologies in patients presenting with HF may influence treatment decisions, such as a need for implantable defibrillator insertion, and provide an opportunity for disease-specific therapy. CMR can readily determine the extent of iron infiltration in thalassemia, hemochromatosis, and other states of iron overload, and quantify them with the use of the T2* sequence. (48)
CMR has advantages over echocardiography in the detection of intraventricular thrombi. (49) Following IV Gd, the blood pool signal is enhanced on T1W images and the signal from thrombus remains low (black). T1W images acquired immediately after administration of Gd can distinguish thrombus from surrounding myocardium or tumor. When imaging immediately after Gd contrast administration, myocardium or tumor demonstrate increased signal due to vascularity and perfusion, whereas thrombus, being avascular, remains dark. Left atrial appendage thrombus can also be seen on CMR, but the diagnostic accuracy of CMR in this area is yet to be determined. (50)
The anatomic mechanisms and quantification severity can be assessed by CMR. Echocardiographic measurements of regurgitation may be inaccurate, particularly in dilated ventricles. (51) The 3-dimensional volumetric nature of CMR helps overcome the problems with inhomogeneity and eccentricity of regurgitant jets. (52) Comparison of LV stroke volume from volumetric LV measurements can be compared with aortic forward flow measurements using phase contrast flow imaging in the ascending aorta. The regurgitant volume can readily be calculated. (53-55) Regurgitant orifice area, most often calculated by the proximal isovelocity surface area (PISA) method in echocardiography, can also be performed by CMR. (56) The CMR measurement of anatomic orifice area, however, has not been prospectively evaluated to provide equivalent prognostic information to echocardiography.
[FIGURE 8 OMITTED]
Similar CMR techniques can be used for quantification of tricuspid, aortic and pulmonary regurgitation. In particular, phase-contrast flow quantification across the semilunar valves offer an accurate measurement of forward and backward flow, (57) and may offer superior reproducibility to echocardiography.
Echocardiography is the best-established non-invasive technique for the evaluation of diastolic dysfunction. (58) Cardiovascular MR analysis of ventricular filling velocity, 3-dimensional myocardial strain analysis and real-time CMR tissue tagging are promising methods to assess regional diastolic function. (59) Cardiovascular MR using phase contrast flow imaging is capable of measuring flow across the mitral valve and in pulmonary veins. Measurements of mitral A-wave and E-wave velocity and deceleration times, and systolic and diastolic wave velocities in the pulmonary flow traces, have been shown to be reliable and easy to obtain. (60) Cardiovascular MR measurements show good correlation with echocardiographic measurements in limited numbers of patients with normal and abnormal ventricles. (60,61)
Arrhythmogenic RV dysplasia
CMR provides the best imaging technique available for assessment of RV free wall contraction abnormalities and is particularly valuable in assessing patients with suspected arrhythmogenic RV dysplasia (ARVD). (62,63) Regional wall motion abnormalities are more difficult to interpret in the RV than in the LV because of the structure of the RV free wall. Exaggerated diastolic distortion of the RV free wall, or the "accordion sign," is also associated with genotype-positive ARVD. (64) However, some systolic distortion of the RV, due to contraction of the moderator band and insertion of the trabeculae into the thin RV free wall, may be present in normal patients. There is also growing recognition of LV involvement in ARVD, which can be imaged by CMR. (62) Identification of fatty infiltration of the RV wall by CMR can be supportive of a diagnosis of ARVD, but is not a reliable sign due to the thinness of the RV wall. It should be noted that fatty infiltration, as defined in the current diagnostic criteria, is a histological diagnosis not an imaging diagnosis, and the prevalence of RV fat by CMR in the normal population has not been fully elucidated.
Improved temporal resolution ECG-gated SSFP images allow approximately 40 frames per heart beat to be obtained. In the 4-chamber view, the LV lateral wall and septal contractility can be carefully evaluated frameby-frame in relation to tricuspid and mitral valve opening as well as atrial contraction. Cardiac MR techniques using SSFP imaging show promise in the evaluation of mechanical dyssynchrony. (65) The improved spatial resolution of CMR, combined with high temporal resolution or real-time imaging, may offer improved reproducibility for the assessment of dyssychrony, which has proven difficult in randomized echocardiographic trials of dyssynchrony quantification. (66-68) The ability for CMR to predict responders to cardiac resynchronization therapy is an area of ongoing research. It has been well demonstrated, however, that patients with a large volume of myocardial scar, as determined by CMR, respond poorly to biventricular pacing. (6)
Constriction and constrictive pericarditis
Contstrictive pericarditis is notoriously difficult to diagnose, often with subtle echocardiographic and invasive hemodynamic findings. CMR provides an accurate assessment of pericardial thickness, using double and triple inversion recovery sequences, as well as being able to non-invasively demonstrate ventricular interdependence. Real-time imaging allows assessment of the ventricular interdependence and abnormal septal motion seen in constrictive physiology. This is done in the LV short axis view with images, including the domes of the diaphragm, in order to observe respiratory motion.
Magnetic resonance angiography
The anatomy of the great vessels and branches are exquisitely shown on CMR, particularly with contrast-enhanced 3-dimensional magnetic resonance angiography (3D-MRA). Lack of ionizing radiation and high reproducibility make 3D-MRA useful for longitudinal follow-up of patients with vascular abnormalities, particularly surgical shunts or dissection. MR pulmonary angiography is also useful in evaluation and surgical planning for chronic thromboembolic disease (Figure 8). (70)
In spite of its advantages, CMR does have some limitations in patients with dysrythmias that affect ECG-gating, claustrophobia, implantable devices, and severe renal impairment. Parallel imaging has improved acquisition time, and automated software has reduced analysis time, however CMR remains a specialized technique requiring considerable expertise for both acquisition and interpretation.
CMR uniquely provides accurate and reproducible measures of volumes and function of all 4 cardiac chambers and surrounding vasculature. It provides excellent morphological information with unparalleled definition between blood pool and myocardium. Combined with the known patterns of LGE, CMR provides a powerful tool for the diagnosis and quantification of myocardial infarction. It provides prognostic information prior to either revascularization or ventriculoplasty. Non-ischemic patterns of LGE may reveal infiltrative conditions that are often difficult to diagnose with other techniques, and which may significantly alter clinical management. CMR is an ideal technique to evaluate complications such as intracardiac thrombus or valve dysfunction. It has significant advantages in evaluation of the RV, which is increasingly recognized as an important and prognostic factor in HF and congenital heart disease.
(1.) Pohost GM. The history of cardiovascular magnetic resonance. J Am Coll Cardiol Img. 2008; 1:672-678.
(2.) Marwick T, Schwaiger M. The future of cardiovascular imaging in the diagnosis and management of heart failure, Part 1. Circ Cardiovas Imaging. 2008; 1:58-69.
(3.) Slaughter R. Congenital heart disease in adults In: Manning W, Braunwald E, eds. Atlas of Cardiovascular Magnetic Resonance. 1 ed: New York, NY: Springer; 2009:153.
(4.) Pennell DJ. Ventricular volume and mass by CMR. J Cardiovasc Magn Reson. 2002;4:507-513.
(5.) Papavassiliu T, Kuhl HP, Schroder M, et al. Effect of endocardial trabeculae on left ventricular measurements and measurement reproducibility at cardiovascular MR imaging. Radiology. 2005;236:57-64.
(6.) Mor-Avi V, Jenkins C, Kuhl HP, et al. Real-time 3dimensional echocardiographic quantification of left ventricular volumes: Multicenter study for validation with magnetic resonance imaging and investigation of sources of error. JACC Cardiovasc Imaging. 2008;1:413-423.
(7.) Nagel E, Lehmkuhl HB, Bocksch W, et al. Noninvasive diagnosis of ischemia-induced wall motion abnormalities with the use of high-dose dobutamine stress MRI: Comparison with dobutamine stress echocardiography. Circulation. 1999;99:763-770.
(8.) Grothues F, Moon JC, Bellenger NG, et al. Interstudy reproducibility of right ventricular volumes, function, and mass with cardiovascular magnetic resonance. Am Heart J. 2004;147:218-223.
(9.) Larose E, Ganz P, Reynolds HG, et al. Right ventricular dysfunction assessed by cardiovascular magnetic resonance imaging predicts poor prognosis late after myocardial infarction. J Am Coll Cardiol. 2007;49:855-862.
(10.) Strugnell WE, Slaughter RE, Riley RA, et al. Modified RV short axis series D\ new method for cardiac MRI measurement of right ventricular volumes. J Cardiovasc Magn Reson. 2005;7:769-774.
(11.) Whitnah J, Mitsumori L, Branch K, et al. Efficiency and reproducibility of the right ventricular horizontal long axis MR imaging plane for the evaluation of right heart function. Proceedings of ISMRM 2006, Seattle, WA, USA, 2006.
(12.) Arheden H, Saeed M, Higgins CB, et al. Measurement of the distribution volume of gadopentetate dimeglumine at echo-planar MR imaging to quantify myocardial infarction: Comparison with 99m Tc-DTPA autoradiography in rats. Radiology. 1999;211:698-708.
(13.) Rolf A, Nef HM, Mollmann H, etal. Immunohistological basis of the late gadolinium enhancement phenomenon in tako-tsubo cardiomyopathy. Eur Heart J. 2009;30:1635-1642.
(14.) Kim RJ, Choi K, Judd RM. Assessment of myocardial viability by contrast enhancement. In: Higgins C and de Roos A, eds. Cardiovascular MRI and MRA. 1 ed. Philadelphia, PA: Lippincot Williams & Wilkins; 2003:209-236.
(15.) Tomlinson DR, Becher H, Selvanayagam JB. Assessment of myocardial viability: Comparison of echocardiography versus cardiac magnetic resonance imaging in the current era. Heart Lung Circ. 2008;17:173-185.
(16.) Weaver JC, McCrohon JA. Contrast-enhanced cardiac MRI in myocardial infarction. Heart Lung Circ. 2008;17:290-298.
(17.) Beek AM, Bondarenko O, Afsharzada F, van Rossum AC. Quantification of late gadolinium enhanced CMR in viability assessment in chronic ischemic heart disease: A comparison to functional outcome. J Cardiovasc Magn Reson. 2009;11:6.
(18.) Thygesen K, Alpert JS, White HD, on behalf of the Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal Definition of Myocardial Infarction. J Am Coll Cardiol. 2007;50:2173-2195.
(19.) Abdel-Aty H, Simonetti O, Friedrich MG. T2weighted cardiovascular magnetic resonance imaging. J Magn Reson Imaging. 2007;26:452-459.
(20.) Aletras AH, Tilak GS, Natanzon A, et al. Retrospective determination of the area at risk for reperfused acute myocardial infarction with T2-weighted cardiac magnetic resonance imaging: Histopathological and displacement encoding with stimulated echoes (DENSE) functional validations. Circulation. 2006;113:1865-1870.
(21.) Francone M, Bucciarelli-Ducci C, Carbone I, et al. Impact of primary coronary angioplasty delay on myocardial salvage, infarct size, and microvascular damage in patients with ST-segment elevation myocardial infarction: Insight from cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54: 2145-2153.
(22.) Abdel-Aty H, Schulz-Menger J. Cardiovascular magnetic resonance T2-weighted imaging of myocardial edema in acute myocardial infarction. Recent Pat Cardiovasc Drug Discov. 2007;2:63-68.
(23.) Kim RJ, Fieno DS, Parrish TB, et al. Relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100:1992-2002.
(24.) Wesbey GE, Higgins CB, McNamara MT, et al. Effect of gadolinium-DTPA on the magnetic relaxation times of normal and infarcted myocardium. Radiology. 1984;153:165-169.
(25.) Rehwald WG, Fieno DS, Chen E-L, et al. Myocardial magnetic resonance imaging contrast agent concentrations after reversible and irreversible ischemic injury. Circulation. 2002;105:224-229.
(26.) Kim RJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med. 2000;343:1445-1453.
(27.) Choi KM, Kim RJ, Gubernikoff G, et al. Transmural extent of acute myocardial infarction predicts long-term improvement in contractile function. Circulation. 2001;104:1101-1107.
(28.) Beek AM, Kuhl HP, Bondarenko O, et al. Delayed contrast-enhanced magnetic resonance imaging for the prediction of regional functional improvement after acute myocardial infarction. J Am Coll Cardiol. 2003;42:895-901.
(29.) Schvartzman PR, Srichai MB, Grimm RA, et al. Nonstress delayed-enhancement magnetic resonance imaging of the myocardium predicts improvement of function after revascularization for chronic ischemic heart disease with left ventricular dysfunction. Am Heart J. 2003;146:535-541.
(30.) Bello D, Shah DJ, Farah GM, et al. Gadolinium cardiovascular magnetic resonance predicts reversible myocardial dysfunction and remodeling in patients with heart failure undergoing beta-blocker therapy. Circulation. 2003;108:1945-1953.
(31.) McCrohon JA, Moon JC, Prasad SK, et al. Differentiation of heart failure related to dilated cardiomyopathy and coronary artery disease using gadolinium-enhanced cardiovascular magnetic resonance. Circulation. 2003;108:54-59.
(32.) Casolo G, Minneci S, Manta R, et al. Identification of the ischemic etiology of heart failure by cardiovascular magnetic resonance imaging: Diagnostic accuracy of late gadolinium enhancement. Am Heart J. 2006;151:101-108.
(33.) Hamilton-Craig C, Layland J, Seleem M, et al. Can CT coronary angiography and cardiac MRI effectively exclude ischaemia in LV dysfunction? A prospective study. Abstract Heart Lung Circ. 2009; 18:S27-S28.
(34.) Lubbers DD, Janssen CH, Kuijpers D, et al. The additional value of first pass myocardial perfusion imaging during peak dose of dobutamine stress cardiac MRI for the detection of myocardial ischemia. IntJ Cardiovasc Imaging. 2008;24:69-76.
(35.) Assomull RG, Prasad SK, Lyne J, et al. Cardiovascular magnetic resonance, fibrosis, and prognosis in dilated cardiomyopathy. J Am Coll Cardiol. 2006;48:1977-1985.
(36.) Strugnell WE, McCann AB, Larsen P, et al. MRI findings in non-ischaemic dilated cardiomyopathy. Australasian Radiology. 2006;50:P9.
(37.) Larsen P, McCann A, Slaughter R, Strugnell W. MRI gadolinium enhancement patterns in patients with dilated cardiomyopathy. Society of Cardiovascular Magnetic Resonance 2007;February 2-4, 2007, Rome, Italy.
(38.) Iles L, Pfluger H, Phrommintikul A, et al. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574-1580.
(39.) Chuang ML, Manning WJ. Left ventricular hypertrophy and excess cardiovascular mortality is late gadolinium enhancement the imaging link? J Am Coll Cardiol. 2009;53:292-294.
(40.) Butler CR, Thompson R, Haykowsky M, et al. Cardiovascular magnetic resonance in the diagnosis of acute heart transplant rejection: A review. J Cardiovasc Magn Reson. 2009;11:7.
(41.) Kwon DH, Smedira NG, Rodriguez ER, et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: Correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol. 2009; 54:242-249.
(42.) Suk T, Edwards C, Hart H, Christiansen JP. Myocardial scar detected by contrast-enhanced cardiac magnetic resonance imaging is associated with ventricular tachycardia in hypertrophic cardiomyopathy patients. Heart, Lung Circ. 2008; 17:370-374.
(43.) Mahrholdt H, Wagner A, Judd RM, et al. Delayed enhancement cardiovascular magnetic resonance assessment of non-ischaemic cardiomyopathies. Eur Heart J. 2005;26:1461-1474.
(44.) Ichinose A, Otani H, Oikawa M, et al. MRI of cardiac sarcoidosis: Basal and subepicardial localization of myocardial lesions and their effect on left ventricular function. AJ RAm J Roentgenol. 2008; 191:862-869.
(45.) Hansen MW, Merchant N. MRI of hypertrophic cardiomyopathy: Part 2, Differential diagnosis, risk stratification, and posttreatment MRI appearances. AJR Am J Roentgenol. 2007;189: 1344-1352.
(46.) vanden Driesen RI, Slaughter RE, Strugnell WE. MR findings in cardiac amyloidosis. AJR Am J Roentgenol. 2006;186:1682-1685.
(47.) Hamilton-Craig CR, Harker J, Strugnell WE, Slaughter RE. Diagnostic features of endomyocardial fibrosis by cardiac MRI. Heart, Lung Circ. 2008;17:S52.
(48.) Anderson LJ, Holden S, Davis B, et al. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Eur Heart J. 2001 ;22:2171-2179.
(49.) Mollet NR, Dymarkowski S, Volders W, et al. Visualization of ventricular thrombi with contrast-enhanced magnetic resonance imaging in patients with ischemic heart disease. Circulation. 2002; 106:2873-2876.
(50.) Ohyama H, Hosomi N, Takahashi T, et al. Comparison of magnetic resonance imaging and transesophageal echocardiography in detection of thrombus in the left atrial appendage. Stroke. 2003;34:2436-2439.
(51.) Schwammenthal E, Chen C, Benning F, et al. Dynamics of mitral regurgitant flow and orifice area. Physiologic application of the proximal flow convergence method: clinical data and experimental testing. Circulation. 1994;90:307-322.
(52.) D'Ancona G, Biondo D, Mamone G, et al. Ischemic mitral valve regurgitation in patients with depressed ventricular function: Cardiac geometrical and myocardial perfusion evaluation with magnetic resonance imaging. Eur J Cardiothorac Surg. 2008; 34:964-968.
(53.) Gelfand EV, Hughes S, Hauser TH, et al. Severity of mitral and aortic regurgitation as assessed by cardiovascular magnetic resonance: Optimizing correlation with Doppler echocardiography. J Cardiovasc Magn Reson. 2006;8:503-507.
(54.) Cawley PJ, Otto CM. Valvular regurgitation: Does cardiovascular magnetic resonance provide additional information compared to echocardiography? Minerva Cardioangiol. 2009;57:521-535.
(55.) Cawley PJ, Maki JH, Otto CM. Cardiovascular magnetic resonance imaging for valvular heart disease: Technique and validation. Circulation. 2009; 119:468-478.
(56.) Buchner S, Debl K, Poschenrieder F, et al. Cardiovascular magnetic resonance for direct assessment of anatomic regurgitant orifice in mitral regurgitation. Circ Cardiovasc Imaging. 2008; 1:148-155.
(57.) Devos DG, Kilner PJ. Calculations of cardiovascular shunts and regurgitation using magnetic resonance ventricular volume and aortic and pulmonary flow measurements. Eur Radiol. 2010;20: 410-421.
(58.) Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr. 2009;22:107-133.
(59.) Paelinck BP, Lamb HJ, Bax JJ, et al. Assessment of diastolic function by cardiovascular magnetic resonance. Am Heart J. 2002;144:198-205.
(60.) Rathi VK, Doyle M, Yamrozik J, et al. Routine evaluation of left ventricular diastolic function by cardiovascular magnetic resonance: A practical approach. J Cardiovasc Magn Reson. 2008;10:36.
(61.) Rubinshtein R, Glockner JF, Feng D, et al. Comparison of magnetic resonance imaging versus Doppler echocardiography for the evaluation of left ventricular diastolic function in patients with cardiac amyloidosis. Am J Cardiol. 2009;103:718-723.
(62.) Jain A, Tandri H, Calkins H, Bluemke DA. Role of cardiovascular magnetic resonance imaging in arrhythmogenic right ventricular dysplasia. J Cardiovasc Magn Reson. 2008;10:32.
(63.) Sen-Chowdhry S, Prasad SK, Syrris P, et al. Cardiovascular magnetic resonance in arrhythmogenic right ventricular cardiomyopathy revisited: Comparison with task force criteria and genotype. J Am Coll Cardiol. 2006;48:2132-2140.
(64.) Dalal D, Tandri H, Judge DP, et al. Morphologic variants of familial arrhythmogenic right ventricular dysplasia/cardiomyopathy: A genetics-magnetic resonance imaging correlation study. J Am Coll Cardiol. 2009;53:1289-1299.
(65.) Koos R, Neizel M, Schummers G, et al. Feasibility and initial experience of assessment of mechanical dyssynchrony using cardiovascular magnetic resonance and semi-automatic border detection. J Cardiovasc Magn Reson. 2008;10:49.
(66.) Marwick TH. Straining the guidelines with dyssynchrony imaging. J Am Soc Echocardiogr. 2009; 22:251-252.
(67.) Marwick TH, Starling RC. The riddle of determining cardiac resynchronization therapy response: A physiologic approach to dyssynchrony therapy. J Am Coll Cardiol. 2008;52:1410-1412.
(68.) Chung ES, Leon AR, Tavazzi L, et al. Results of the predictors of response to CRT (PROSPECT) trial. Circulation. 2008;117:2608-2616.
(69.) White JA, Yee R, Yuan X, et al. Delayed enhancement magnetic resonance imaging predicts response to cardiac resynchronization therapy in patients with intraventricular dyssynchrony. J Am CollCardiol. 2006;48:1953-1960.
(70.) Hamilton-Craig C, Kermeen F, Dunning JJ, Slaughter RE. Cardiovascular magnetic resonance prior to surgical treatment of chronic thromboembolic pulmonary hypertension. Eur Heart J. 2010;31:1040.
Christian R. Hamilton-Craig, MD, FRACP, Richard E. Slaughter, MD, FRANZCR, and Jeffrey H. Maki, MD, PhD
Dr. Hamilton-Craig is a Staff Cardiologist, Center of Excellence for Cardiovascular MRI, University of Queensland, Brisbane, Australia, and Department of Radiology, University of Washington, Seattle, WA; Dr. Slaughter is Director of Medical Imaging, Centre of Excellence in Cardiovascular MRI, The Prince Charles Hospital, Brisbane, Australia; and Dr. Maki is Director of Body MRI, University of Washington Medical Centre, Seattle, WA. Dr Hamilton-Craig is supported by the National Heart Foundation of Australia and the University of Washington Trans-Pacific Fellowship.
Table 1. Common Indications and Contraindications for CMR in Patients with Heart Failure Common Indications * Accurate assessment of left ventricular ejection fraction for device implantation (ICD/CRT) * Myocardial viability (ischemic cardiomyopathies) * Detection of interventricular thrombus * Interstitial fibrosis (dilated and infiltrative cardiomyopathies) * Congenital heart disease * Right ventricular quantification * Evaluation for ARVD/C * Post cardiac transplantation surveillance * Constrictive pericarditis * Quantification of valvular dysfunction * Aortic and vascular measurement * Iron overload quantification (T2*) Contraindications Absolute * Non-MR compatible implantable devices * Severe claustrophobia Relative * Dysrhythmia affecting ECG-gating * Severe renal impairment (risk of nephrogenic systemic fibrosis) ICD = implantable cardiac defibrillator. CRT = cardiac resynchronization therapy, ARVD/C = arrythmogenic right ventricular dysplasia/cardiomyopathy. Table 2. Delayed Enhancement Patterns in CMR Ischemic * Subendocardial or full thickness enhancement cardiomyopathies in atypical coronary distribution (Figure 4) Non-ischemic * Mid-wall, often mild enhancement cardiomyopathies Hypertrophic * Patchy mid-wall enhancement in the areas cardiomyopathy of myocardial thickening * Faint "plexiform fibrosis" enhancement * Auto-infarction due to burnt-out disease (Figure 7E) Sarcoidosis * Patchy,often bright LGE in a non-coronary distribution Myocarditis * Mid-wall LGE in the lateral LV (Figure 7A) Amyloidosis * Thickened myocardium with diffuse LGE of relatively low signal, involving both ventricles and the atria. Systemic auto- * Subendocardial and/or subepicardial immune syndromes enhancement * Areas of full thickness LGE (Figure 7B) Endomyocardial * Bright subendocardial enhancement in a fibrosis shortened ventricle * Often with triangular-shaped LV apical thrombus (Figure 7F). Iron overload * Low signal on SSFP imaging * Quantification with T2 * 1 LGE = late gadolinium enhancement, SSFP = steady state free precession, LV = left ventricle
|Printer friendly Cite/link Email Feedback|
|Author:||Hamilton-Craig, Christian R.; Slaughter, Richard E.; Maki, Jeffrey H.|
|Date:||Nov 1, 2010|
|Previous Article:||Agenesis of the dorsal pancreas.|
|Next Article:||Imaging non-obstetrical causes of abdominal pain in the pregnant patient.|